公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements | Kudo M.; Han K.-H.; Ye S.-L.; Zhou J.; Huang Y.-H.; Lin S.-M.; Wang C.-K.; Ikeda M.; Chan S.L.; Choo S.P.; Miyayama S.; ANN-LII CHENG | Liver Cancer | 150 | 146 | |
2014 | Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries | Dan Y.Y.; Wong J.B.; Hamid S.S.; Han K.-H.; Jia J.D.; CHUN-JEN LIU ; Piratvisuth T.; Lok A.S.F.; Lim S.G. | Hepatology International | 10 | 8 | |
2015 | Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014) | CHIUN HSU ; BANG-BIN CHEN ; CHIEN-HUNG CHEN ; MING-CHIH HO ; CHIA-HSIEN CHENG ; Kokudo N.; Murakami T.; Yeo W.; Seong J.; Jia J.-D.; Han K.-H.; ANN-LII CHENG | Liver Cancer | 17 | 22 | |
2013 | Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC) | Park J.-W.; Amarapurkar D.; Chao Y.; PEI-JER CHEN ; Geschwind J.-F.H.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; ANN-LII CHENG | Liver International | 69 | 60 | |
2019 | Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6) | Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG ; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W. | British Journal of Cancer | 2 | 2 | |
2010 | Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy | Lui Y.Y.-N.; Tsoi K.K.-F.; Wong V.W.-S.; JIA-HORNG KAO ; Hou J.-L.; Teo E.-K.; Mohamed R.; Piratvisuth T.; Han K.-H.; Mihm U.; Wong G.L.-H.; Chan H.L.-Y. | Antiviral Therapy | 35 | 37 | |
2010 | Eastern asian expert panel opinion: Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma | Yeo W.; PEI-JER CHEN ; Furuse J.; Han K.-H.; CHIUN HSU ; Lim H.-Y.; Moon H.; Qin S.; Yeoh E.-M.; Ye S.-L. | BMC Cancer | 4 | 4 | |
2018 | The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C | Younossi Z.M.; Stepanova M.; Henry L.; Han K.-H.; Ahn S.H.; Lim Y.-S.; Chuang W.-L.; JIA-HORNG KAO ; Kinh N.; Lai C.L.; Yuen M.-F.; Chan H.L.-Y.; Lai W. | Liver International | 17 | 12 | |
2012 | Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia | Afdhal N.H.; Giannini E.G.; Tayyab G.; Mohsin A.; Lee J.-W.; Andriulli A.; Jeffers L.; McHutchison J.; PEI-JER CHEN ; Han K.-H.; Campbell F.; Hyde D.; Brainsky A.; Theodore D. | New England Journal of Medicine | 240 | 215 | |
2014 | Eltrombopag increases platelet numbers in thrombocytopenic patients with hcv infection and cirrhosis, allowing for effective antiviral therapy | Afdhal N.H.; Dusheiko G.M.; Giannini E.G.; PEI-JER CHEN ; Han K.-H.; Mohsin A.; Rodriguez-Torres M.; Rugina S.; Bakulin I.; Lawitz E.; Shiffman M.L.; Tayyab G.-U.-N.; Poordad F.; Kamel Y.M.; Brainsky A.; Geib J.; Vasey S.Y.; Patwardhan R.; Campbell F.M.; Theodore D. | Gastroenterology | 104 | 103 | |
2008 | Erratum: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update (Hepatology International 10.1007/s12072-008-9080-3) | Liaw Y.-F.; Leung N.; JIA-HORNG KAO ; Teerha P.; Gane E.; Han K.-H.; Guan R.; Lau G.K.K.; Locarnini S. | Hepatology International | 0 | 0 | |
2012 | Erratum: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update (Hepatology International (2012) 6 (531-561) DOI: 10.1007/s12072-012-9365-4) | Liaw Y.-F.; JIA-HORNG KAO ; Piratvisuth T.; Chan H.L.Y.; Chien R.-N.; CHUN-JEN LIU ; Gane E.; Locarnini S.; Lim S.-G.; Han K.-H.; Amarapurkar D.; Cooksley G.; Jafri W.; Mohamed R.; Hou J.-L.; Chuang W.-L.; Lesmana L.A.; Sollano J.D.; Suh D.-J.; Omata M. | Hepatology International | 16 | 18 | |
2010 | Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts'opinion | PEI-JER CHEN ; Furuse J.; Han K.-H.; CHIUN HSU ; Lim H.-Y.; Moon H.; Qin S.; Ye S.-L.; Yeoh E.-M.; Yeo W. | Liver International | 37 | 34 | |
2018 | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Kudo M.; Finn R.S.; Qin S.; Han K.-H.; Ikeda K.; Piscaglia F.; Baron A.; Park J.-W.; Han G.; Jassem J.; Blanc J.F.; Vogel A.; Komov D.; Evans T.R.J.; Lopez C.; Dutcus C.; Guo M.; Saito K.; Kraljevic S.; Tamai T.; Ren M.; ANN-LII CHENG | The Lancet | 3442 | 3008 | |
2011 | Needs for hepatocellular carcinoma control policy in the Asia-Pacific region | Bridges J.F.P.; Joy S..; Gallego G.; Kudo M.; Ye S.-L.; Han K.-H.; ANN-LII CHENG ; Blauvelt B. | Asian Pacific Journal of Cancer Prevention | 25 | ||
2016 | No Evidence of Reactivation of Hepatitis B Virus among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection | Sulkowski M.S.; Chuang W.-L.; JIA-HORNG KAO ; Yang J.C.; Gao B.; Brainard D.M.; Han K.-H.; Gane E. | Clinical Infectious Diseases | 56 | 56 | |
2021 | Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: From the phase III REFLECT study | Finn R.S.; Kudo M.; ANN-LII CHENG ; Wyrwicz L.; Ngan R.K.C.; Blanc J.-F.; Baron A.D.; Vogel A.; Ikeda M.; Piscaglia F.; Han K.-H.; Qin S.; Minoshima Y.; Kanekiyo M.; Ren M.; Dairiki R.; Tamai T.; Dutcus C.E.; Ikezawa H.; Funahashi Y.; Evans T.R.J. | Clinical Cancer Research | 32 | 29 | |
2014 | Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel | ANN-LII CHENG ; Amarapurkar D.; Chao Y.; PEI-JER CHEN ; Geschwind J.-F.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Park J.-W. | Liver International | 74 | 69 | |
2015 | Reimbursement policies in the Asia-Pacific for chronic hepatitis B | Lim S.G.; Amarapurkar D.N.; Chan H.L.-Y.; Crawford D.H.; Gane E.J.; Han K.-H.; Ahn S.H.; Jafri W.; Jia J.; JIA-HORNG KAO ; Lesmana L.A.; Lesmana C.R.A.; Mohamed R.; Phiet P.H.; Piratvisuth T.; Sarin S.K.; Sollarno J.D.; Eguchi Y.; Mahtab M.-A.; Lee K.H. | Hepatology International | 21 | 19 | |
2011 | Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score | Yang H.-I.; Yuen M.-F.; Chan H.L.Y.; Han K.-H.; PEI-JER CHEN ; Kim D.-Y.; Ahn S.-H.; Chen C.-J.; Wong V.W.S.; Seto W.-K. | The Lancet Oncology | 502 | 479 |